<p>High adherence level to artemisinin-based combination therapies in rural settlement 11 years after their introduction in the health system, Nanoro, Burkina Faso</p>

Regimen Pill Artemether Univariate analysis
DOI: 10.2147/ppa.s190927 Publication Date: 2019-02-27T21:43:35Z
ABSTRACT
Purpose: In 2005, Burkina Faso changed its first-line treatment for uncomplicated malaria from chloroquine to artemisinin-based combination therapies (ACTs). Patient adherence ACTs regimen is a keystone achieve the expected therapeutic outcome and prevent emergence spread of parasite resistance. Eleven years after introduction in health system, this study aimed measure level patients rural settlement investigate determinants nonadherence. Patients methods: The was carried out at public peripheral facilities May 2017 August Nanoro district, Faso. An electronic semi-structured questionnaire used data collection with an ACT prescription their medical consultation exit visit during home day 5±2. Adherence measured through self-report pill counts. Logistic regression performed identify factors Results: analysis conducted on 199 outpatients who received as prescription. About 92.5% prescriptions included artemether-lumefantrine tablets. 97.0% Of these, 86.0% were classified “complete adherent” 14.0% “nonadherent”. univariate analysis, patients/caregivers considered that affordability easy seemed be less adherent (OR: 0.26; 95% CI: 0.07–0.70). multivariable analyses, did not receive advices care workers (HCWs) more likely nonadherent prescribed (adjusted OR: 3.21; 1.13–9.12). Conclusion: This demonstrates majority those get comply recommended regimen. emphasizes settings where are provided free charge or subsidized price, patient high, thus minimizing risk subtherapeutic concentrations drug blood which known increase resistance susceptibility new infections. Therefore, address problem nonadherence, strategy strengthen communication between HCWs should given greater consideration. Keywords: malaria, hyperendemic area, prescription, artemether-lumefantrine, amodiaquine-artesunate
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (4)